LENSAR Inc

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LENSAR Inc (LNSR) reports strong Q1 growth and eyes global expansion

LENSAR Inc (LNSR) delivered robust financial performance in Q1 2024, marked by revenue and procedure growth, expansion of ALLY systems, and market share gains. While facing regulatory challenges and competition, the company's strong financial position and growth opportunities position it well for the future. Continued focus on innovation and market expansion will be key for sustained success.

LENSAR Inc (LNSR) reports robust Q3 earnings, eyes global expansion

LENSAR's Q3 2024 performance reflects strong growth momentum and operational improvements.
While challenges like cost management and market competition persist, the company's strategic strengths position it well for future opportunities.
By capitalizing on its successful international launch and focusing on revenue-driving strategies, LENSAR is poised for continued growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that it has completed the installation of multiple ALLY Systems in five private equity-owned (“PE-owned”) ophthalmology groups, including EyeSouth Partners' network. EyeSouth Partners is one of the largest PE-owned ophthalmic focused, premier networks in the U.S., with.

LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups

LENSAR, Inc. (NASDAQ:LNSR ) Q1 2023 Earnings Conference Call May 15, 2023 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Chris Bolster - Propel Advisory Operator Good morning, ladies and gentlemen and welcome to the LENSAR Inc. First Quarter 2023 Financial Results Conference Call. At this time, all lines are in a listen-only mode.

LENSAR, Inc. (LNSR) Q1 2023 Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2023 and provided an update on key operational initiatives. “I am thrilled with the growing momentum ALLY is experiencing. It has exceeded our expectations thus far, both in terms of systems and procedure volumes,” said.

LENSAR Reports First Quarter 2023 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's first quarter 2023 financial results will be released before market open on Monday, May 15, 2023. LENSAR's management will host a conference call and webcast at 8:30 am ET on Monday, May 15, 2023 to discuss the financial results and recent corporate.

LENSAR to Report First Quarter 2023 Financial Results on Monday, May 15, 2023

LENSAR, Inc. (NASDAQ:LNSR ) Q4 2022 Earnings Call Transcript March 16, 2023 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nick Curtis - Chief Executive Officer Tom Staab - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Operator Good morning, and thank you for your participation. At this time, all participants are in a listen-only mode.

LENSAR, Inc. (LNSR) Q4 2022 Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives.

LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2022 financial results will be released before market open on Thursday, March 16, 2023.

LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022 and its cash balance as of December 31, 2022, and provided an update on the launch of its ALLY® Adaptive Cataract Treatment System.

LENSAR Announces Preliminary Fourth Quarter and Full Year 2022 Results

ORLANDO, Fla.--( BUSINESS WIRE )--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer will present at two upcoming investor conferences:

LENSAR to Present at Two Upcoming Investor Conferences

LENSAR, Inc. (NASDAQ:LNSR ) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nick Curtis - Chief Executive Officer Tom Staab - Chief Financial Officer Conference Call Participants Samuel Brodovsky - BTIG Operator Good morning, ladies and gentlemen. Thank you for standing by.

LENSAR, Inc. (LNSR) Q3 2022 Earnings Call Transcript

LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update

LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY™ Adaptive Cataract Treatment System (“ALLY” or the “ALLY System”) in the European Union. “Following the FDA clearance of ALLY in June 2022 and recent U.S. commercial launch, this is another important step in our effort to b

LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EU

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the first commercial cases performed with the ALLY™ Adaptive Cataract Treatment System (“ALLY” or the “ALLY System”) by Robert Weinstock, MD at The Eye Institute of West Florida. Dr. Weinstock performed 15 laser-assisted cataract surgery cases following the recent inst

First Patients Treated with LENSAR's® ALLY™ Adaptive Cataract Treatment System

LENSAR, Inc. (NASDAQ:LNSR ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Operator Good morning and thank you for your participation. At this time, all participants are in a listen-only mode.

LENSAR, Inc. (LNSR) CEO Nicholas Curtis on Q2 2022 Results - Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2022 and provided an update on operational initiatives. “In June, we achieved a significant milestone in LENSAR's history, the Food and Drug Administration (“FDA”)'s clearance of our ALLY Adaptive Cataract Treatment Syst

LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's second quarter 2022 financial results will be released before market open on Monday, August 8, 2022. LENSAR's management will host a conference call and webcast at 8:30 am ET on Monday, August 8, 2022 to discuss the financial results and recent corpo

LENSAR to Report Second Quarter 2022 Financial Results on Monday, August 8, 2022

The FDA granted 510(k) clearance to Lensar Inc's (NASDAQ: LNSR) next-generation ALLY Adaptive Cataract Treatment System (ALLY System). ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond-laser-assisted cataract surgery (FLACS).

Why Lensar Shares Are Trading Higher Today

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its next-generation ALLY Adaptive Cataract Treatment System (“ALLY” or “ALLY System”). ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond-laser-assisted cataract

LENSAR® Receives U.S. FDA Clearance of ALLY™ Adaptive Cataract Treatment System

LENSAR, Inc. (NASDAQ:LNSR ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nick Curtis - Chief Executive Officer Tom Staab - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Danielle Antalffy - SVB Operator Good morning, and thank you for your participation. At this time, all participants are in a listen-only mode.

LENSAR, Inc. (LNSR) CEO Nick Curtis on Q1 2022 Results - Earnings Call Transcript

LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of 23.86% and 4.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LENSAR, Inc. (LNSR) Reports Q1 Loss, Tops Revenue Estimates

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2022 and provided an update on operational initiatives. “We have started 2022 on an impressive note by achieving more than 30% growth in both revenue and worldwide procedure volumes as compared to the first quarter of l

LENSAR Reports First Quarter 2022 Financial Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's first quarter 2022 financial results will be released before market open on Monday, May 9, 2022. LENSAR's management will host a conference call and webcast at 8:30 am ET on Monday, May 9, 2022 to discuss the financial results and recent corporate hi

LENSAR to Report First Quarter 2022 Financial Results on Monday, May 9, 2022

LENSAR, Inc. (LNSR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LENSAR, Inc. (LNSR) Q1 Earnings Expected to Decline

LENSAR, Inc. (LNSR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

News for LENSAR Inc Stock (LNSR)